

Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Early Infant Diagnosis (EID) of HIV is an essential component of efforts to prevent mother-to-child transmission (PMTCT) and reduce the burden of pediatric HIV/AIDS. This paper explores the impact of EID on preventing HIV transmission in newborns and its broader implications for health systems strengthening. Through an analysis of current literature and emerging trends, this review highlights the critical role of EID in empowering health systems to effectively combat the HIV/AIDS epidemic and ensure the well-being of future generations. The significance of EID in identifying HIV-exposed infants promptly after birth, facilitating timely initiation of antiretroviral therapy (ART), and reducing vertical transmission rates is underscored. However, challenges in universal access to EID services persist, including limited healthcare infrastructure, human resource constraints, logistical barriers, and social stigma. Addressing these challenges requires comprehensive strategies to strengthen health systems and promote equitable access to EID services. The implications of EID for health systems strengthening are profound, offering opportunities to improve service delivery, enhance coordination of care, and optimize resource allocation. By prioritizing investment in EID programs and promoting multisectoral collaboration, health systems can effectively address the HIV/AIDS epidemic and ensure a healthier future for all.

Keywords: *Early Infant Diagnosis, HIV Prevention, Mother-to-Child Transmission, Pediatric HIV, Antiretroviral Therapy, Health Systems Strengthening*

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33

Introduction

Preventing the transmission of HIV from mother to child is a paramount objective in global health, particularly in regions where HIV prevalence rates remain high. Early Infant Diagnosis (EID) of HIV plays a crucial role in achieving this goal by enabling the timely identification of HIV-exposed infants and facilitating prompt initiation of interventions. By detecting HIV infection early in infancy, EID programs contribute significantly to preventing mother-to-child transmission (MTCT) of HIV and improving health outcomes for newborns. This introduction sets the stage for an exploration of the impact of EID on preventing HIV transmission in newborns and its broader implications for health systems strengthening. The significance of EID within the context of PMTCT efforts cannot be overstated. EID allows healthcare providers to identify HIV-exposed infants shortly after birth, enabling timely initiation of antiretroviral therapy (ART) and other essential interventions. By integrating EID into PMTCT programs, significant progress has been made in reducing vertical transmission rates and improving survival outcomes for HIV-exposed infants. However, challenges in universal access to EID services persist, particularly in resource-limited settings where healthcare infrastructure and resources are scarce. Despite its importance, universal access to EID services remains a significant challenge in many regions. Limited healthcare infrastructure, shortages of trained personnel, logistical barriers, and social stigma surrounding HIV/AIDS hinder the effective delivery of EID services to all infants in need. Addressing these challenges requires comprehensive strategies to strengthen health systems, enhance service delivery, and promote community engagement in EID programs. Furthermore, the implications of EID for health systems strengthening are profound. By integrating EID services into existing maternal and child health programs, health systems can streamline service delivery, improve coordination of care, and optimize resource allocation. Investments in EID infrastructure, capacity-building, and quality assurance mechanisms contribute to building resilient health systems capable of responding effectively to the evolving challenges of the HIV/AIDS epidemic.¹⁻³⁰

Significance of Early Infant Diagnosis in Preventing Mother-to-Child Transmission

Early Infant Diagnosis (EID) holds immense significance in preventing mother-to-child transmission (MTCT) of HIV, playing a pivotal role in safeguarding the health of newborns and interrupting the cycle of HIV transmission within communities. EID enables healthcare providers to promptly identify infants born to HIV-positive mothers, allowing for early detection of HIV infection. Timely identification of HIV-exposed infants is crucial for initiating appropriate interventions promptly, including antiretroviral therapy (ART) and prophylactic measures, to reduce the risk of HIV transmission and improve health outcomes. Early diagnosis through EID facilitates prompt initiation of ART in HIV-infected infants, which is essential for suppressing viral replication and preserving immune function. Initiation of ART early in life significantly reduces the risk of disease progression, AIDS-related morbidity, and mortality, thus improving long-term health outcomes for HIV-infected infants. EID plays a critical role in preventing disease progression and reducing mortality rates among HIV-infected infants. Early diagnosis allows for timely monitoring of disease progression and initiation of appropriate interventions, such as ART

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33

and management of opportunistic infections, which are essential for improving survival outcomes and reducing the burden of pediatric HIV/AIDS. Early diagnosis through EID is essential for interrupting the chain of transmission of HIV from mother to child. By identifying HIV-infected infants early in life and initiating appropriate interventions, EID programs reduce the likelihood of onward transmission of the virus within families and communities, thus contributing to the broader goal of reducing the overall burden of HIV/AIDS. EID is an integral component of Prevention of Mother-to-Child Transmission (PMTCT) programs, which aim to prevent the transmission of HIV from mother to child during pregnancy, childbirth, and breastfeeding. By ensuring the early identification of HIV-exposed infants and facilitating their access to comprehensive care and treatment services, EID programs strengthen PMTCT efforts and contribute to achieving global targets for HIV prevention and treatment.³¹⁻⁵⁰

Challenges in Universal Access to EID Services

Universal access to Early Infant Diagnosis (EID) services remains a significant challenge, particularly in resource-limited settings where the burden of HIV/AIDS is most acute. Many regions, especially in low-income countries, lack adequate healthcare infrastructure to support comprehensive EID programs. This includes shortages of healthcare facilities, trained personnel, and laboratory equipment necessary for conducting diagnostic tests. In rural or remote areas, the scarcity of healthcare facilities further exacerbates the challenge of accessing EID services. Shortages of trained healthcare personnel, including laboratory technicians, nurses, and clinicians, pose a significant barrier to the provision of EID services. In many resource-limited settings, healthcare workers are overburdened and may lack the necessary training to conduct EID testing and provide appropriate care to HIV-exposed infants. Addressing human resource constraints requires investment in training programs and workforce development initiatives to build capacity in EID service delivery.⁵¹⁻⁵⁵

Logistical barriers, such as sample transportation and laboratory processing times, can delay the delivery of test results and impede timely diagnosis and treatment initiation for HIV-exposed infants. Inadequate transportation networks, lack of cold chain storage facilities, and lengthy turnaround times for test results can hinder the effectiveness of EID programs, particularly in remote or rural areas where access to healthcare services is limited. Social stigma surrounding HIV/AIDS remains a significant barrier to EID uptake, particularly in communities where HIV-related discrimination and prejudice are prevalent. Fear of disclosure, misconceptions about HIV/AIDS, and cultural beliefs may deter caregivers from seeking EID testing for their infants or adhering to treatment recommendations. Addressing social and cultural barriers requires targeted community engagement and education efforts to promote awareness, acceptance, and uptake of EID services. Financial barriers, including out-of-pocket costs for testing and treatment, can pose challenges for caregivers seeking EID services for their infants. In many resource-limited settings, healthcare services are not fully covered by public health insurance schemes, leaving families to bear the financial burden of healthcare costs. Addressing financial constraints requires policy interventions to ensure that EID services are affordable and accessible to all families, regardless of socioeconomic status.⁵⁶⁻⁶⁰

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*, 2023; 1 (1): 23-33

Implications for Health Systems Strengthening

The implications of Early Infant Diagnosis (EID) for health systems strengthening are profound, offering opportunities to enhance the delivery of healthcare services, improve coordination of care, and optimize resource allocation. EID services can be integrated into existing maternal and child health programs, leveraging existing infrastructure and personnel to expand access to testing services. By incorporating EID into routine antenatal and postnatal care visits, health systems can streamline service delivery and ensure that HIV-exposed infants receive timely testing and appropriate interventions. Early Infant Diagnosis (EID) requires robust laboratory infrastructure and diagnostic capacity to conduct accurate and reliable testing. Strengthening laboratory systems, including the procurement of laboratory equipment, training of laboratory technicians, and implementation of quality assurance measures, is essential for ensuring the reliability and validity of EID test results. Investments in laboratory capacity-building contribute to broader efforts to strengthen health systems and improve diagnostic capabilities for HIV/AIDS and other infectious diseases. Early Infant Diagnosis (EID) programs generate substantial amounts of data related to testing, treatment, and patient outcomes. Developing and implementing robust data management and reporting systems are essential for tracking progress, monitoring program performance, and informing decision-making. Electronic medical record systems, health information exchange platforms, and other digital health solutions facilitate the collection, analysis, and dissemination of EID-related data, enabling healthcare providers and policymakers to make informed decisions and allocate resources effectively. Effective delivery of EID services requires a skilled and knowledgeable healthcare workforce. Investing in training programs and capacity-building initiatives for healthcare personnel, including clinicians, nurses, laboratory technicians, and community health workers, is essential for ensuring the successful implementation of EID programs. Building capacity among healthcare personnel enhances their ability to conduct EID testing, provide counseling and support to caregivers, and deliver comprehensive care and treatment services to HIV-exposed infants. Community engagement and partnerships play a critical role in strengthening EID programs and improving access to testing services. Engaging community stakeholders, including community health workers, peer educators, and advocacy groups, fosters trust, promotes awareness, and increases uptake of EID services among vulnerable populations. Collaborating with community-based organizations and non-governmental organizations (NGOs) enhances the reach and effectiveness of EID programs, particularly in hard-to-reach or marginalized communities.⁶¹⁻⁷⁰

Conclusion

Early Infant Diagnosis (EID) of HIV plays a pivotal role in preventing mother-to-child transmission (MTCT) and advancing global efforts to combat the HIV/AIDS epidemic. The significance of EID in identifying HIV-exposed infants promptly after birth, facilitating timely initiation of antiretroviral therapy (ART), and reducing vertical transmission rates cannot be overstated. However, challenges in universal access to EID services persist, including limitations in healthcare infrastructure, human resource constraints, logistical barriers, social stigma, and financial constraints. Despite these challenges, the implications of EID for health systems

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33

strengthening are profound. By integrating EID services into maternal and child health programs, strengthening laboratory and diagnostic capacity, enhancing data management systems, building capacity among healthcare personnel, and promoting community engagement and partnerships, health systems can effectively address the HIV/AIDS epidemic and ensure the well-being of HIV-exposed infants and their families.

References

1. Shrivastava R, Fonjungo PN, Kebede Y, Bhimaraj R, Zavahir S, Mwangi C, Gadde R, Alexander H, Riley PL, Kim A, Nkengasong JN. Role of public-private partnerships in achieving UNAIDS HIV treatment targets. *BMC health services research*. 2019; 19:1-10.
2. Kiyaga C, Narayan V, McConnell I, Elyanu P, Kisaakye LN, Joseph E, Kekitiinwa A, Grosz J. Uganda's "EID Systems Strengthening" model produces significant gains in testing, linkage, and retention of HIV-exposed and infected infants: an impact evaluation. *Plos one*. 2021;16(2): e0246546.
3. Abrams EJ, Strasser S. 90-90-90—Charting a steady course to end the paediatric HIV epidemic. *Journal of the International AIDS Society*. 2015; 18:20296.
4. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
5. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
6. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
7. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
8. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
9. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
10. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*, 2023; 1 (1): 23-33

11. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
12. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
13. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
14. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
15. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
16. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
17. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
18. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State, Nigeria. *J. Bio. Innov*. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev*. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH),

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*, 2023; 1 (1): 23-33

- Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)
21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](#)
 22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
 23. Obeagu EI, Ameorpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.
[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
 24. Obeagu EI, Scott GY, Ameorpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
 25. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022;29-34.
 26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
 27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.
[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](#).
 28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](#) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](#)
 29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](#) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](#).

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. Elite Journal of Public Health, 2023; 1 (1): 23-33

30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014)
https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
32. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: [DOI: 10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137)
[links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://www.researchgate.net/publication/35344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).
33. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
34. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211.
<http://research.sdpublishers.net/id/eprint/2819/>.
35. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International.* 2021;33(57A):360-368.
36. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):6-15.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
37. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research,* 2023; 10(8): 564-568
38. Nwosu DC, Nwanjo HU, Okolie NJ, Ikech K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences,* 2015; 4(3): 153-160.

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*, 2023; 1 (1): 23-33

[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](#).

39. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
40. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](#)
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](#).
41. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](#) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](#).
42. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](#).
43. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
44. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
45. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
46. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
47. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
48. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*, 2023; 1 (1): 23-33

49. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
50. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
51. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
52. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
53. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
54. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
55. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
56. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
57. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
58. Echefu SN, Udosen JE, Akwivu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
59. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
60. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.
61. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2023;10(11):14-25.

Citation: Obeagu EI, Obeagu GU. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*, 2023; 1 (1): 23-33

62. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
63. Katoba J, Kuupiel D, Mashamba-Thompson TP. Toward improving accessibility of point-of-care diagnostic services for maternal and child health in low-and middle-income countries. *Point of care.* 2019;18(1):17-25.
64. Sallam M, Alabbadi AM, Abdel-Razeq S, Battah K, Malkawi L, Al-Abbadi MA, Mahafzah A. HIV knowledge and stigmatizing attitude towards people living with HIV/AIDS among medical students in Jordan. *International Journal of Environmental Research and Public Health.* 2022;19(2):745.
65. Nayak S, Blumenfeld NR, Laksanasopin T, Sia SK. Point-of-care diagnostics: recent developments in a connected age. *Analytical chemistry.* 2017;89(1):102-123.
66. Kang T, Lu J, Yu T, Long Y, Liu G. Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example. *Biosensors and Bioelectronics.* 2022; 206:114109.
67. Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science,* 2023; 1(1):1-11
68. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. *Elite Journal of Health Science,* 2023; 1(1):12-22
69. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. *Elite Journal of Public Health,* 2023; 1 (1): 1-11
70. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. *Elite Journal of Public Health,* 2023; 1 (1): 12-22